This clinical study is exploring the effects of a new drug, **navicixizumab**, either alone or with other cancer treatments, on certain advanced cancers. The study involves four groups of patients with different types of cancer, including **CRC** (colon/rectal cancer), **gastric and GEJ cancer** (stomach and gastroesophageal junction cancer), **TNBC** (triple-negative breast cancer), and **platinum-resistant ovarian cancer**. Participants will receive treatment in **4-week cycles** and undergo regular check-ups, including heart and tumor monitoring. The study will continue until the tumor grows, side effects become intolerable, or the patient or doctor decides to stop. **CT scans** are used to track tumor progress, and heart function is checked using **echocardiograms**. Key Points:

• Participants must be at least 18 years old and have specific types of advanced cancer.
• The study involves regular visits, heart and tumor monitoring, and follow-up calls after treatment ends.
• Female participants must use effective birth control and have a negative pregnancy test to join.